NOVA MSC BERHAD
12 December 2023
| Type | Announcement |
| Subject | OTHERS |
| Description | Press Release – Nova MSC’s Revolutionary AI Tool, SELENA+, Selected for Oman’s National DR Screening Program |
Nova MSC Berhad (the “Company”) is pleased to attach a press release entitled “Nova MSC’s Revolutionary AI Tool, SELENA+, Selected for Oman’s National DR Screening Program”. Please refer to the attachment for the details of the press release.
Eyris Pte Ltd (“Eyris”), has been awarded a contract to provide first level AI diabetic retinopathy diagnostic screening result to Oman’s National DR Screening Program for two years. Due to a confidentiality clause in a partnership agreement signed between Eyris and the partner in Oman, the Company is unable to disclose specific details regarding the name of the partner, contract value, its renewability, and the duration of any renewed license for ‘SELENA+’, as the disclosure could potentially impact Eyris and the partner’s commercial interests.
The said contract is not expected to have any material impact to the result of the Group for the financial year ending 31 March 2024. It will also not any effect on the share capital and shareholding structure of Nova MSC Berhad.
Eyris does not expect any material risk arising from the contract other than the normal operational risk associated with the contract.
None of the directors and/or substantial shareholders of Nova MSC Berhad or persons connected to the said directors and/or substantial shareholders have any interest, direct or indirect in the new contract awarded.
This announcement is dated 12 December 2023.
Please refer attachment below.
Nova MSCs Revolutionary AI Tool SELENA Selected for Omans National DR Screening Program
Comments are closed.